Abusing 10 mg Of Cyclobenzaprine To Get High - Recreational Use Could Be Costly ☆☆☆☆☆ 0
5 1

Abusing 10 mg Of Cyclobenzaprine To Get High – Recreational Use Could Be Costly

Listen to the content
Table of Content
Cyclobenzaprine High
Allergic Reactions
Cyclobenzaprine And Alcohol
Cyclobenzaprine’s Classification

Cyclobenzaprine 10mg High: Learn about the experience and effects of using Cyclobenzaprine recreationally. Cyclobenzaprine (aka Flexeril) is a potent muscle relaxer prescribed to alleviate painful musculoskeletal conditions and ease muscle spasms.

Chemically associated with a drug family called tricyclic antidepressants, Cyclobenzaprine emerged as one of the first depression medications in the 1950s. Similar to the way tricyclics treat depression, Cyclobenzaprine prevents reuptake of norepinephrine and serotonin so the brain is exposed to increased levels of these two mood transmitters.

  • In addition, researchers think Cyclobenzaprine blocks nerve impulses traveling to the brain, providing pain relief.

Recommended Dosages

According to the National Institute of Health: “The recommended dosage in adults is 5 to 10 mg, three times daily, for 3 to 4 weeks. It comes in extended release pills of 15 and 30 mg.

It is available in tablets of 5 and 10 mg in multiple generic forms and under the trade names of;

  • Flexeril
  • Flexamid
  • Amrix

It was approved for use in the United States in 1977 and it remains widely used with more than 10 million prescriptions filled yearly.

It is usually administered for limited periods of time.

Common side effects include sleepiness, dry mouth, dizziness and headache.

Cyclobenzaprine 10mg High

According to the FDA, “Pharmacologic similarities among the tricyclic drugs require that certain withdrawal symptoms be considered when FLEXERIL is administered, even though they have not been reported to occur with this drug.

According to the DOJ “Anecdotal reports found on the Internet suggest that individuals are taking cyclobenzaprine alone or in combination with other illicit drugs to produce or enhance psychoactive effects. Individuals have reported taking cyclobenzaprine both orally and intranasally at doses ranging from 10 mg to 60 mg.”

It goes on to say “Sedation, relaxation and increased heart rate were the most common effects reported. Euphoria was reported by a smaller number of individuals.”

According to the NIH “While muscle relaxants have abuse potential, we did not find studies describing abuse of cyclobenzaprine.”

Can Cyclobenzaprine 10mg Get Someone High?

Yes, it is possible to get high on as little as 10mg of Cyclobenzaprine.

For musculoskeletal pain and spasms, doctors typically prescribe 10 mg of Cyclobenzaprine two or three times daily. For severe pain, dosage can be increased to 60 mg daily.

  • However, prescriptions are written as a two week supply only because of Flexeril’s potential for abuse and addiction.

Especially for new Cyclobenzaprine users, a Cyclobenzaprine 10 mg high is possible until they develop a tolerance for the drug’s sedating effects.

Is Cyclobenzaprine And Drinking Alcohol Okay?

Combining Cyclobenzaprine with alcohol or other central nervous depressant will enhance the sedative effects of Cyclobenzaprine. Brain functioning becomes severely impaired, breathing may slow significantly and heart rate can drop to shock levels.

  • If enough Cyclobenzaprine and alcohol are taken simultaneously, the user risks complete suppression of the respiratory system and or heart failure.

Flexeril also increases depressant qualities of other drugs such as antihistamines, antidepressants, narcotic pain medications and other muscle relaxants. Taking Cyclobenzaprine with MAO inhibitors ( brands like Marplan, Nardil, Parnate) may cause death. If you are taking an MAO, doctors will make you stop taking the MAO at least two weeks before you begin using a cyclobenzaprine product.

Cyclobenzaprine Is Not A Narcotic

A narcotic is defined as a psychoactive drug associated with opioids and opiates that induces sleep and is a derivative of raw opium compounds.

  • Cyclobenzaprine is not a narcotic
  • It is classified as a tricyclic amine salt (does not target opioid receptors in the brain)

Is Cyclobenzaprine a Controlled Substance?

No, it is not a cyclobenzaprine is not a controlled substance. According to DOJ Drug Enforcement Administration Office of Diversion Control Drug & Chemical Evaluation Section, “Cyclobenzaprine is not controlled under the Controlled Substances Act (CSA).”

Cyclobenzaprine Addiction

The U.S. Drug Enforcement Agency does not classify Cyclobenzaprine as a drug presenting potential addiction risks. However some people, when they discover its sedative, muscle relaxing effects, start abusing it. People who end up abusing Cyclobenzaprine for its psychoactive properties can easily develop high tolerance levels.

  • Cyclobenzaprine does cause unpleasant side effects and withdrawal symptoms if someone addicted to Flexeril abruptly stops taking it.


Although rare, Flexeril users can have life-threatening allergic reactions to Cyclobenzaprine. Indications of an allergic reaction involve;

  • swelling of the lips, throat and tongue
  • difficulty breathing
  • hives
  • Anaphylaxis (a real possibility for anyone experiencing an allergic reaction)

Also, by interfering with normal neurotransmitter levels in the brain, Flexeril, and other medications containing Cyclobenzaprine, may cause abusers to suffer anticholinergic toxidrome. It can also prevent cholinergic neurotransmission to specific receptors in the brain.

Symptoms of anticholinergic toxidrome caused by Cyclobenzaprine abuse may include:

  • Confusion, delirium and/or altered mental status
  • Paranoia
  • Fever, flushing
  • Abnormal pupil dilation
  • Inability to urinate
  • Hypertension
  • Tachycardia

Unless treated, severe anticholinergic toxidrome may lead to coma, seizures and heart attack.


Give us your feedback about this page here


Share Your Experience - Submit Review Here - Thank You

Please Comment About Your Experience Today, Thank You!

Your email address will not be published. Required fields are marked *